About Us

Our Company

Neurocrine Biosciences, Inc of San Diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs.

The Company's research and development efforts are focused on neurological and endocrine diseases and disorders.  Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders.

Pipeline Highlights

The Company has a rich and diversified pipeline with compounds in all phases of clinical development.

Neurocrine's Pipeline

GnRH Antagonists

Neurocrine is currently conducting a third Phase IIb trial known as the Tulip Petal Study or the 703 Study.  This trial consists of four arms, elagolix 150mg once daily, elagolix 250mg once daily, Prostap SR3.75mb® (Lupron), and placebo.  This study is being conducted in Central Eastern Europe and is currently enrolling subjects with a laparoscopic diagnosis of endometriosis.  Top-line data from the initial three month double-blind treatment period of approximately 180 patients is expected during the fourth quarter of this year.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and IBS. GSK has completed the first Phase II "proof of concept" clinical trial with a lead CRF1 receptor antagonist compound, 876008, for SocAD and has completed recruiting for a Phase II "proof of concept" clinical trial in IBS.

Urocortin 2 for congestive heart failure (CHF):

Neurocrine licensed urocortin 2 to further expand the Company’s franchise in corticotropin-releasing factor (CRF) research.

Research Programs

Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine's chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems necessary to deliver one new drug candidate every 12 months.

Neurocrine Biosciences Corporate Information

The Company’s common stock is traded on the Nasdaq Global Select Market System under the symbol “NBIX”

Contact Information